Seroprevalence of Bactericidal, Specific IgG Antibodies and Incidence of Meningitis Due to Group A Neisseria meningitidis by Age in Burkina Faso 2008

Caroline L. Trotter; Seydou Yaro; Berthe Marie Njanpop-Lafourcade; Aly Drabo; Sita S. Kroman; Regina S. Idohou; Oumarou Sanou; Leah Bowen; Helen Findlow; Serge Diagbouga; Bradford D. Gessner; Ray Borrow; Judith E. Mueller

doi:10.1371/journal.pone.0055486

Seroprevalence of Bactericidal, Specific IgG Antibodies and Incidence of Meningitis Due to Group A Neisseria meningitidis by Age in Burkina Faso 2008

Caroline L. Trotter, Seydou Yaro, Berthe Marie Njanpop-Lafourcade, Aly Drabo, Sita S. Kroman, Regina S. Idohou, Oumarou Sanou, Leah Bowen, Helen Findlow, Serge Diagbouga, Bradford D. Gessner, Ray Borrow, Judith E. Mueller

Research output: Contribution to journal › Article › peer-review

27 Citations (Scopus)

Abstract

Background: We investigated serological correlates of protection against Neisseria meningitidis serogroup A (NmA) in Burkina Faso before the introduction of NmA conjugate vaccine. Methodology/Principal Findings: We collected blood from a representative sample (N = 1022) of Bobo-Dioulasso residents. Sera were evaluated for serum bactericidal antibody (SBA) activity against NmA strains of immunotype L11 (F8238) and L10 (3125) and NmA-specific IgG. Seroprevalence was compared to the age-specific NmA meningitis incidence in Bobo-Dioulasso during March 2007-February 2008. Meningococcal carriage was evaluated in a subset (N = 538). Geometric mean titres (GMT)/concentrations (GMC) of SBA and NmA-specific IgG increased with age, peaking around age 20 years. Overall, 70% of our sample had NmA-specific IgG ≥2 ug/mL. Meningitis incidence was highest in those aged <6 months and 5-19 years. No NmA carriers were found. Compared to the reference strain SBA, GMTs were higher against a locally isolated strain and around 40-fold lower against Dutch strain 3125. Conclusions/Significance: This study provides estimates of natural immunity to NmA, according to a variety of antibody measures, which will be helpful in ascertaining antibody persistence after MenAfriVac™ introduction. Age-specific seroprevalence of reference strain SBA titres most likely reflects exposure to meningococci and consecutive reactive immunity. We could not define any serological correlate of protection.

Original language	English
Article number	e55486
Journal	PLoS ONE
Volume	8
Issue number	2
DOIs	https://doi.org/10.1371/journal.pone.0055486
Publication status	Published - 14 Feb 2013
Externally published	Yes

Bibliographical note

Funding Information:
BL, SSK, OS, RSI, and BDG work, and JEM until recently worked, for the Agence de Médecine Préventive, which receives unrestricted support from Sanofi Pasteur as well as grant specific support from Sanofi Pasteur, GlaxoSmithKline, Pfizer, and Merck. RB and HF have performed contract research on behalf of the Health Protection Agency, funded by Pfizer, Novartis Vaccines, Baxter Bioscience, GlaxoSmithKline, Sanofi Pasteur, Sanofi Pasteur MSD, Alexion Pharmaceuticals Inc, and Merck. All other authors declare no conflicts of interest. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pone.0055486

Cite this

Trotter, C. L., Yaro, S., Njanpop-Lafourcade, B. M., Drabo, A., Kroman, S. S., Idohou, R. S., Sanou, O., Bowen, L., Findlow, H., Diagbouga, S., Gessner, B. D., Borrow, R., & Mueller, J. E. (2013). Seroprevalence of Bactericidal, Specific IgG Antibodies and Incidence of Meningitis Due to Group A Neisseria meningitidis by Age in Burkina Faso 2008. PLoS ONE, 8(2), Article e55486. https://doi.org/10.1371/journal.pone.0055486

@article{f2bbe70b5d5c44c79e702472222e260f,

title = "Seroprevalence of Bactericidal, Specific IgG Antibodies and Incidence of Meningitis Due to Group A Neisseria meningitidis by Age in Burkina Faso 2008",

abstract = "Background: We investigated serological correlates of protection against Neisseria meningitidis serogroup A (NmA) in Burkina Faso before the introduction of NmA conjugate vaccine. Methodology/Principal Findings: We collected blood from a representative sample (N = 1022) of Bobo-Dioulasso residents. Sera were evaluated for serum bactericidal antibody (SBA) activity against NmA strains of immunotype L11 (F8238) and L10 (3125) and NmA-specific IgG. Seroprevalence was compared to the age-specific NmA meningitis incidence in Bobo-Dioulasso during March 2007-February 2008. Meningococcal carriage was evaluated in a subset (N = 538). Geometric mean titres (GMT)/concentrations (GMC) of SBA and NmA-specific IgG increased with age, peaking around age 20 years. Overall, 70% of our sample had NmA-specific IgG ≥2 ug/mL. Meningitis incidence was highest in those aged <6 months and 5-19 years. No NmA carriers were found. Compared to the reference strain SBA, GMTs were higher against a locally isolated strain and around 40-fold lower against Dutch strain 3125. Conclusions/Significance: This study provides estimates of natural immunity to NmA, according to a variety of antibody measures, which will be helpful in ascertaining antibody persistence after MenAfriVac{\texttrademark} introduction. Age-specific seroprevalence of reference strain SBA titres most likely reflects exposure to meningococci and consecutive reactive immunity. We could not define any serological correlate of protection.",

author = "Trotter, {Caroline L.} and Seydou Yaro and Njanpop-Lafourcade, {Berthe Marie} and Aly Drabo and Kroman, {Sita S.} and Idohou, {Regina S.} and Oumarou Sanou and Leah Bowen and Helen Findlow and Serge Diagbouga and Gessner, {Bradford D.} and Ray Borrow and Mueller, {Judith E.}",

note = "Funding Information: BL, SSK, OS, RSI, and BDG work, and JEM until recently worked, for the Agence de M{\'e}decine Pr{\'e}ventive, which receives unrestricted support from Sanofi Pasteur as well as grant specific support from Sanofi Pasteur, GlaxoSmithKline, Pfizer, and Merck. RB and HF have performed contract research on behalf of the Health Protection Agency, funded by Pfizer, Novartis Vaccines, Baxter Bioscience, GlaxoSmithKline, Sanofi Pasteur, Sanofi Pasteur MSD, Alexion Pharmaceuticals Inc, and Merck. All other authors declare no conflicts of interest. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. ",

year = "2013",

month = feb,

day = "14",

doi = "10.1371/journal.pone.0055486",

language = "English",

volume = "8",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "2",

}

Trotter, CL, Yaro, S, Njanpop-Lafourcade, BM, Drabo, A, Kroman, SS, Idohou, RS, Sanou, O, Bowen, L, Findlow, H, Diagbouga, S, Gessner, BD, Borrow, R & Mueller, JE 2013, 'Seroprevalence of Bactericidal, Specific IgG Antibodies and Incidence of Meningitis Due to Group A Neisseria meningitidis by Age in Burkina Faso 2008', PLoS ONE, vol. 8, no. 2, e55486. https://doi.org/10.1371/journal.pone.0055486

TY - JOUR

T1 - Seroprevalence of Bactericidal, Specific IgG Antibodies and Incidence of Meningitis Due to Group A Neisseria meningitidis by Age in Burkina Faso 2008

AU - Trotter, Caroline L.

AU - Yaro, Seydou

AU - Njanpop-Lafourcade, Berthe Marie

AU - Drabo, Aly

AU - Kroman, Sita S.

AU - Idohou, Regina S.

AU - Sanou, Oumarou

AU - Bowen, Leah

AU - Findlow, Helen

AU - Diagbouga, Serge

AU - Gessner, Bradford D.

AU - Borrow, Ray

AU - Mueller, Judith E.

N1 - Funding Information: BL, SSK, OS, RSI, and BDG work, and JEM until recently worked, for the Agence de Médecine Préventive, which receives unrestricted support from Sanofi Pasteur as well as grant specific support from Sanofi Pasteur, GlaxoSmithKline, Pfizer, and Merck. RB and HF have performed contract research on behalf of the Health Protection Agency, funded by Pfizer, Novartis Vaccines, Baxter Bioscience, GlaxoSmithKline, Sanofi Pasteur, Sanofi Pasteur MSD, Alexion Pharmaceuticals Inc, and Merck. All other authors declare no conflicts of interest. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

PY - 2013/2/14

Y1 - 2013/2/14

N2 - Background: We investigated serological correlates of protection against Neisseria meningitidis serogroup A (NmA) in Burkina Faso before the introduction of NmA conjugate vaccine. Methodology/Principal Findings: We collected blood from a representative sample (N = 1022) of Bobo-Dioulasso residents. Sera were evaluated for serum bactericidal antibody (SBA) activity against NmA strains of immunotype L11 (F8238) and L10 (3125) and NmA-specific IgG. Seroprevalence was compared to the age-specific NmA meningitis incidence in Bobo-Dioulasso during March 2007-February 2008. Meningococcal carriage was evaluated in a subset (N = 538). Geometric mean titres (GMT)/concentrations (GMC) of SBA and NmA-specific IgG increased with age, peaking around age 20 years. Overall, 70% of our sample had NmA-specific IgG ≥2 ug/mL. Meningitis incidence was highest in those aged <6 months and 5-19 years. No NmA carriers were found. Compared to the reference strain SBA, GMTs were higher against a locally isolated strain and around 40-fold lower against Dutch strain 3125. Conclusions/Significance: This study provides estimates of natural immunity to NmA, according to a variety of antibody measures, which will be helpful in ascertaining antibody persistence after MenAfriVac™ introduction. Age-specific seroprevalence of reference strain SBA titres most likely reflects exposure to meningococci and consecutive reactive immunity. We could not define any serological correlate of protection.

AB - Background: We investigated serological correlates of protection against Neisseria meningitidis serogroup A (NmA) in Burkina Faso before the introduction of NmA conjugate vaccine. Methodology/Principal Findings: We collected blood from a representative sample (N = 1022) of Bobo-Dioulasso residents. Sera were evaluated for serum bactericidal antibody (SBA) activity against NmA strains of immunotype L11 (F8238) and L10 (3125) and NmA-specific IgG. Seroprevalence was compared to the age-specific NmA meningitis incidence in Bobo-Dioulasso during March 2007-February 2008. Meningococcal carriage was evaluated in a subset (N = 538). Geometric mean titres (GMT)/concentrations (GMC) of SBA and NmA-specific IgG increased with age, peaking around age 20 years. Overall, 70% of our sample had NmA-specific IgG ≥2 ug/mL. Meningitis incidence was highest in those aged <6 months and 5-19 years. No NmA carriers were found. Compared to the reference strain SBA, GMTs were higher against a locally isolated strain and around 40-fold lower against Dutch strain 3125. Conclusions/Significance: This study provides estimates of natural immunity to NmA, according to a variety of antibody measures, which will be helpful in ascertaining antibody persistence after MenAfriVac™ introduction. Age-specific seroprevalence of reference strain SBA titres most likely reflects exposure to meningococci and consecutive reactive immunity. We could not define any serological correlate of protection.

UR - http://www.scopus.com/inward/record.url?scp=84874007673&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0055486

DO - 10.1371/journal.pone.0055486

M3 - Article

C2 - 23457471

AN - SCOPUS:84874007673

SN - 1932-6203

VL - 8

JO - PLoS ONE

JF - PLoS ONE

IS - 2

M1 - e55486

ER -

Seroprevalence of Bactericidal, Specific IgG Antibodies and Incidence of Meningitis Due to Group A Neisseria meningitidis by Age in Burkina Faso 2008

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this